中关村(000931.SZ)：下属公司北京华素盐酸羟考酮缓释片（10mg）收到国家药品监督管理局《受理通知书》

Core Viewpoint - Zhongguancun (000931.SZ) announced that its subsidiary Beijing Huasu Pharmaceutical Co., Ltd. has received a Notice of Acceptance from the National Medical Products Administration for the application of Oxycodone Hydrochloride Controlled-Release Tablets (10mg) [1] Group 1 - The application for Oxycodone Hydrochloride Controlled-Release Tablets is accepted for marketing, indicating progress in the drug approval process [1] - Oxycodone is a pure opioid receptor agonist, selectively targeting the μ receptor, and is used clinically for treating severe pain that requires long-term opioid therapy [1] - The primary therapeutic effect of Oxycodone is analgesia, which is crucial for patients with pain that cannot be adequately managed by alternative treatments [1]